Trials and therapies in secondary progressive MS, simplified

Nat Rev Neurol. 2019 Aug;15(8):431-432. doi: 10.1038/s41582-019-0233-x.

Authors

Navid Manouchehri¹, Olaf Stüve^{2

3}

Affiliations

¹ Department of Neurology and Neurotherapeutics, the University of Texas Southwestern Medical Center, Dallas, TX, USA.
² Department of Neurology and Neurotherapeutics, the University of Texas Southwestern Medical Center, Dallas, TX, USA. olaf.stuve@utsouthwestern.edu.
³ Neurology Section, VA North Texas Health Care System, Medical Service Dallas, VA Medical Center, Dallas, TX, USA. olaf.stuve@utsouthwestern.edu.

PMID: 31285578
DOI: 10.1038/s41582-019-0233-x

No abstract available

MeSH terms

Azetidines / therapeutic use*
Benzyl Compounds / therapeutic use*
Cladribine / therapeutic use*
Clinical Trials as Topic
Drug Approval
Humans
Immunosuppressive Agents / therapeutic use*
Multiple Sclerosis, Chronic Progressive / diagnosis
Multiple Sclerosis, Chronic Progressive / drug therapy*
Treatment Outcome
United States

Substances

Azetidines
Benzyl Compounds
Immunosuppressive Agents
Cladribine
siponimod